HSBC Holdings plc Analysts Give Novartis AG (NOVN) a CHF 90 Price Target
Several other brokerages have also issued reports on NOVN. Jefferies Group LLC set a CHF 100 price target on Novartis AG and gave the stock a buy rating in a report on Monday, June 5th. Deutsche Bank AG set a CHF 78 price target on Novartis AG and gave the stock a neutral rating in a report on Wednesday, June 21st. Barclays PLC set a CHF 65 price target on Novartis AG and gave the stock a sell rating in a report on Friday, June 2nd. S&P Global set a CHF 82 price target on Novartis AG and gave the stock a neutral rating in a report on Tuesday, July 18th. Finally, Goldman Sachs Group, Inc. (The) set a CHF 80 price target on Novartis AG and gave the stock a neutral rating in a report on Thursday, July 20th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and seven have assigned a buy rating to the stock. Novartis AG currently has an average rating of Hold and an average target price of CHF 85.
Shares of Novartis AG (NOVN) opened at 82.95 on Tuesday. Novartis AG has a 1-year low of CHK 67.40 and a 1-year high of CHK 84.35. The firm has a 50-day moving average price of CHK 81.20 and a 200 day moving average price of CHK 78.64. The company has a market cap of CHK 194.34 billion and a PE ratio of 30.28.
ILLEGAL ACTIVITY NOTICE: “HSBC Holdings plc Analysts Give Novartis AG (NOVN) a CHF 90 Price Target” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/22/hsbc-holdings-plc-analysts-give-novartis-ag-novn-a-chf-90-price-target.html.
About Novartis AG
Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.
Receive News & Stock Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related stocks with our FREE daily email newsletter.